superman wrote:TOUCH program. This program is non existent outside of he US, another reason for the cases in Euro.
Thanks for your opinion, Superman. But I don´t believe that France would have an exception from the guideline of EMEA - which suggests TYGRIS program for Europe.
As far as all the european PML patients have survived (2 Germans and one from Sweden), one could conclude that TYGRIS program catches PML far earlier than the TOUCH one.
How is it out of France? Tysabri patients have tons of tests in Czech republic too, including MRI being repeated every 6 months. Furthermore patients have to pass psychological investigation every sixth month, too. It´s because "symptoms of PML can include changes in thinking, memory, and orientation leading to confusion and personality changes".
The Czech neuros will try to make few weeks of holidays in Tysabri treatment after 10 or 12 infusions, now. We´ll see if dr. Jung (in the end of http://www.medscape.com/viewarticle/585512
) is right.
It looks like the Tys treatment is one continuous trial, doesn´t it? The trial paid by NHS, not by pharmaceutical company...
Forgive me mentioning the revenue of Biogen/Elan, please. I can´t help myself - Czech NHS has to spend a lot of additional costs while there is not enought money for treatment of all patients who could benefit from DMD´s. In contrast of the rest of the world we can´t get the treatment after the first relaps. Despite the fact that early treatment is the most effective, the Czech patients have to wait till the sesond/the third relaps.